Q1 21 Biopharma Earnings Analysis and Industry Outlook May 2021 (pdf) - EY
Q1 2021 Biopharma earnings analysis and industry outlook
May 2021
Disclaimer
? The views expressed by the authors are not necessarily those of Ernst & Young LLP or other members of the global EY organization.
? This material has been prepared for general informational purposes only and is not intended to be relied upon as accounting, tax, legal or other professional advice. Please refer to your advisors for specific advice.
? This report is ? 2021 Ernst & Young LLP. All Rights Reserved.
Page 1
Q1 21 Biopharma earnings analysis and industry outlook
Q1 2021 Earnings summary
Company AbbVie Amgen AstraZeneca Biogen Bristol Myers Squibb Eli Lilly Gilead GlaxoSmithKline Johnson & Johnson Merck & Co. Novartis Novo Nordisk Pfizer Regeneron Roche Sanofi Teva
Source: S&P Capital IQ, Analyst reports
Y-O-Y Revenue 50.90% -4.20% 15.20% -23.80%
2.70% 16.10% 15.80% -9.70% 7.90% 0.20% -0.10% 6.80% 44.60% 38.3% -1.40% 1.90% -8.60%
Page 2
Company sales vs. consensus 1.30% -5.70% 4.60% -1.70% -0.70% -2.20% -5.00% -6.00% 1.40% -4.50% -0.60% 4.4% 7.10% -1.6% -0.20% 1.60% -1.60%
Change in analyst estimate for FY21 revenue 0.60% -1.60% -0.07% 0.10% -0.30% -1.50% 0.00% -0.50% 0.60% -0.40% -0.80% 0.30% -0.03% 2.2% NA 0.10% -0.01%
Y-O-Y change in EBITDA margin
2.4 pp -2.5 pp -4.5 pp -16.5 pp -0.5 pp -0.6 pp 2.6 pp -2.3 pp 2.0 pp 2.0 pp -0.4 pp -2.9 pp -3.5 pp 5.3 pp
NA 2.4 pp -2.4 pp
Q1 21 Biopharma earnings analysis and industry outlook
EPS (US$) $2.00 $2.90 $1.20 $2.70 $0.90 $1.50 $1.40 $0.30 $2.40 $1.30 $0.90 $0.90 $0.90 $10.60 NA $1.50 $0.10
EPS (%) -1.20% -7.80% 100% -66.60%
NA -7% 12% -24.60% 7% -1.60% -4.40% 15.3% 44% 86% NA -0.50% 11%
Analyst rating*
Buy Buy Buy Hold Buy Buy Buy Hold Buy Buy Buy Hold Buy Buy Buy Buy Hold
Click on the button for more details
Biopharma stock performance
? AbbVie's stock outperformed, on the back of Allergan acquisition and significant investment by Berkshire Hathaway ? Gilead was significantly impacted by COVID-19 pandemic and pricing pressure ? Both the DRG Pharma and the NYSE Arca Biotech index underperformed the S&P 500, due to uncertainty about drug pricing and
regulatory impacts on biopharma companies under the Biden administration
Stock price charts for LTM (May 2020 to April 2021)
180.0
1Q'21
160.0
140.0
120.0
100.0
80.0
60.0 May 20
Jun 20
Jul 20 Abbvie
Aug 20 Sep 20 Oct 20
Merck & Co.
Eli Lilly
Nov 20 Dec 20
GSK
Gilead
Jan 21 DRG
Feb 21 Mar 21 Apr 21
NYSE Biotech
S&P 500
S&P 500 +47.7% AbbVie +34.6% Eli Lilly +18.97% NYSE Biotech +11.8% DRG +11.2% Merck -4.1% GSK -16.9% Gilead -20.6%
Source: S&P 500, NYSE Biotech, DRG, Analyst reports Page 3
Q1 21 Biopharma earnings analysis and industry outlook
EY outlook
1 Revenue performance and earnings results in Q1 21 reflect a high degree of variability across the industry. "Steady as you go" can be a risky strategy.
2 Concerns about drug pricing, reimbursement and tax reforms coming from a new administration are weighing on share prices, and this is likely to continue.
3 A renaissance of scientific innovation continues to drive a favorable growth outlook.
4 The health of the capital markets, as well as IPOs, follow-ons, SPACs and M&A, will significantly impact growth strategies.
Page 4
Q1 21 Biopharma earnings analysis and industry outlook
Back button
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- financial risk in the biotechnology industry national bureau of
- ngm biopharmaceuticals annual report 2021 stocklight
- introduction current status of biopharmaceuticals approved products
- commercialization process of biopharmaceuticals development ijimt
- an overview of the u s medical devices and biopharmaceutical industries
- guide to analytical testing of biopharmaceuticals
- initial public offerings biopharma biotech and pharma websites
- just how good an investment is the biopharmaceutical sector
- biopharmaceutical sector update on the financing and deal torreya
- ngm biopharmaceuticals annual report 2022 stocklight
Related searches
- dept labor and industry pa
- pa labor and industry unemployment
- pa dept of labor and industry website
- labor and industry website
- pa dept of labor and industry forms
- pa dept of labor and industry unemployment
- sector and industry performance
- 2020 2021 pdf fafsa
- general business and industry specialist
- pa dept of labor and industry twitter
- pa department of labor and industry pua
- dept of labor and industry pa